Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PETROS PHARMACEUTICALS, INC.

(PTPI)
 SummaryQuotesChartsNewsCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/18/2021 06/21/2021 06/22/2021 06/23/2021 06/24/2021 Date
3.46(c) 3.51(c) 3.11(c) 3.33(c) 3.18(c) Last
145 571 544 593 604 883 207 761 51 521 Volume
-5.72% +1.45% -11.40% +7.07% -4.50% Change
More quotes
Estimated financial data (e) (USD)
Sales 2019 15,6 M - -
Net income 2019 -32,5 M - -
Net Debt 2019 12,3 M - -
P/E ratio 2019 -
Yield 2019 -
Sales 2020 9,56 M - -
Net income 2020 -20,6 M - -
Net cash position 2020 9,33 M - -
P/E ratio 2020 -1,14x
Yield 2020 -
Capitalization 31,2 M 31,2 M -
EV / Sales 2019 -
EV / Sales 2020 3,49x
Nbr of Employees 27
Free-Float 63,3%
More Financials
Company
Petros Pharmaceuticals, Inc. is focused on identifying, developing, acquiring and commercializing therapeutics for men’s health issues. The Company focuses on various men’s health issues, including erectile dysfunction (ED), endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie’s disease (acute and chronic), hormone health and substance use disorders. Its lead asset is Stendra (avanafil),... 
More about the company
All news about PETROS PHARMACEUTICALS, INC.
06/02PETROS PHARMACEUTICALS  : to Present at the LD Micro Virtual Invitational Confer..
PR
05/17PETROS PHARMACEUTICALS  : Announces First Quarter Financial Results and Provides..
PR
05/17PETROS PHARMACEUTICALS  : Earnings Flash (PTPI) PETROS PHARMACEUTICALS Reports Q..
MT
05/14PETROS PHARMACEUTICALS  : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
AQ
05/14PETROS PHARMACEUTICALS  : to Participate at the Investor Summit Conference and P..
PR
05/07PETROS PHARMACEUTICALS  : to Participate at the Benzinga Global Small Cap Confer..
PR
04/06PETROS PHARMACEUTICALS, INC.  : Entry into a Material Definitive Agreement, Fina..
AQ
03/31PETROS PHARMACEUTICALS  : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
AQ
03/18PETROS PHARMACEUTICALS  : Recently Published Research on Stendra®(avanafil) for ..
PR
02/25PETROS PHARMACEUTICALS, INC.  : Change in Directors or Principal Officers (form ..
AQ
02/18PETROS PHARMACEUTICALS  : Welcomes Dr. Mohit Khera to Steering Committee to Expa..
PR
02/04PETROS PHARMACEUTICALS  : Establishes Steering Committee to Expand into Non-Rx S..
PR
01/25PETROS PHARMACEUTICALS  : Promotes Mitchell Arnold to Principal Financial Office..
MT
01/25PETROS PHARMACEUTICALS, INC.  : Change in Directors or Principal Officers (form ..
AQ
01/19PETROS PHARMACEUTICALS, INC.  : Regulation FD Disclosure (form 8-K)
AQ
More news
News in other languages on PETROS PHARMACEUTICALS, INC.

- No features available -

More news
Chart PETROS PHARMACEUTICALS, INC.
Duration : Period :
Petros Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
John David Shulman Chairman & Chief Executive Officer
Fady Boctor President & Chief Commercial Officer
Mitchell S. Arnold Chief Financial & Accounting Officer
Bruce Todd Bernstein Independent Director
Gregory Bradley Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PETROS PHARMACEUTICALS, INC.-27.73%31
MODERNA, INC.110.72%88 392
LONZA GROUP AG16.70%53 670
IQVIA HOLDINGS INC.34.45%46 441
CELLTRION, INC.-22.42%33 607
SEAGEN INC.-10.13%28 564